In a research report issued Friday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of IntelliPharmaCeutics Intl Inc (USA) (NASDAQ :IPCI), …
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) announced that it has filed a New Drug Application (“NDA”) with the U.S.
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) reported the results of operations for the three and nine months ended August 31, 2016. All dollar amounts referenced …
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) investors cheer the news that the Canadian drug maker has entered into a license and commercial supply agreement with …
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) confirms that as of the date of this news release, they are not aware of any corporate developments …
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid …
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral …
Intellipharmaceutics International Inc. (NASDAQ:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage …
